A new weight-loss medication may soon be available in the United States. Arena pharmaceuticals has filed a new drug application with the FDA for lorcaserin, a selective serotonin 2C-receptor agonist, and will likely get a formal review this fall.
In a large, well-designed observational study of patients with COPD, treatment with β-blockers during a mean follow-up period of 7.2 years was found not only to reduce the risk of exacerbations, but also to improve survival.
Obstructive sleep apnea is associated with an increased risk of incident heart failure in community-dwelling middle-aged and older men, but not in women.
Use of simply obtained historical, physical, and laboratory data can distinguish gout from other forms of arthritis in many patients and avoid joint aspiration.
